Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in Japan

Avatar photo
Business Intelligence

SAN DIEGO, May 26, 2023 /PRNewswire/ — Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be eligible to receive treatment with Daiichi Sankyo’s VANFLYTA® (quizartinib). The assay is available, both as a kit for purchase and as a testing service, worldwide.

In June 2019, the LeukoStrat CDx FLT3 Mutation Assay was approved in Japan as a companion diagnostic for relapsed or refractory FLT3-ITD positive AML. As of May 25, 2023, health insurance will now also cover use of the test for the selection of newly diagnosed FLT3-ITD positive patients. 

The expanded insurance reimbursement was based on a pivotal, clinical bridging study, which demonstrated that efficacy was maintained for patients selected with the LeukoStrat CDx FLT3 Mutation Assay compared to patients selected by the FLT3-ITD Clinical Trial Assay (CTA) in the pivotal QuANTUM-First trial of VANFLYTA. The LeukoStrat CDx FLT3 Mutation Assay successfully selected patients for QuANTUM-First, which formed the basis for the approval of VANFLYTA in newly diagnosed patients in Japan.

Based on these results, health insurance coverage in Japan will be expanded to include use of the companion diagnostic assay for identification of patients that may be eligible to receive front line treatment with VANFLYTA.

“We are proud to be Daiichi Sankyo’s companion diagnostic partner as they offer the first FLT3 inhibitor approved as a de novo treatment option for patients with FLT3-ITD positive AML in Japan,” said Jeffrey Miller, CEO and CSO at Invivoscribe. “This milestone demonstrates the utility of the LeukoStrat CDx FLT3 Mutation Assay in international clinical trials, as well as Invivoscribe’s commitment to improving the lives of patients with AML.”

AML is a blood cancer that affects the blood and bone marrow and is characterized by the rapid growth of abnormal white blood cells.1 AML has the lowest 5-year survival rate (31.7%) among people diagnosed with leukemia.2 About 25% of AML patients have a FLT3-ITD mutation, which contributes to the growth and survival of cancer cells and is associated with a poor prognosis.3

About Invivoscribe
Invivoscribe is a global, vertically-integrated biotechnology company dedicated to Improving Lives with Precision Diagnostics®. For nearly thirty years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality standardized reagents, tests, bioinformatics tools, and services to advance the field of precision medicine. Invivoscribe has a successful track record of partnerships with global pharmaceutical companies, providing expertise in diagnostic development and regulatory submission through commercialization of companion diagnostics. For additional information, please visit www.invivoscribe.com.

https://www.cancer.net/cancer-types/leukemia-acute-myeloid-aml/introduction
https://seer.cancer.gov/statfacts/html/amyl.html 
3 Daver N et al. Leukemia (2019) 33:299–312. 

Logo – https://mma.prnewswire.com/media/1019746/Invivoscribe_Logo.jpg

View original content:https://www.prnewswire.com/apac/news-releases/invivoscribe-announces-updated-reimbursement-for-the-leukostrat-cdx-flt3-mutation-assay-to-select-newly-diagnosed-flt3-itd-positive-aml-patients-eligible-for-vanflyta-in-japan-301835215.html

SOURCE Invivoscribe, Inc.

相關文章

澳門行政長官賀一誠祝賀《澳門商業雜誌》成立二十周年

《澳門商業雜誌》和本集團Project Asia Corporation於本周五(5月24日)舉辦酒會,慶祝成立20周年。 澳門行政長官賀一誠致函《澳門商業雜誌》,對雜誌成立二十周年表示祝賀。

首季零售業銷售額按年減少12.5%

澳門統計暨普查局資料顯示,今年第1季零售業銷售額按年減少12.5%至207.1億澳門元,主要是因為去年首季經濟活動復常,消費需求集中釋放而形成高比較基數所致。

政府要求社團辦橫琴旅行團刺激澳門消費

當局敦促澳門社團利用特區政府最新推出的資助和電子消費券計劃,推廣橫琴旅遊,提振澳門城市經濟。

【總監之言】我們

引用Tomasi de Lampedusa的一句名言:為了有所改變,我們必須讓一切保持原狀。 

與新時代一同崛起

二十載風雨兼程,改變的不僅僅是澳門。我們改變了,世界也改變了。二十年前,澳門正沉醉於博彩市場開放初期帶來的興奮,這一決定最終成功將小城打造成世界頂尖的博彩中心,投注量及營運商和政府收入均領先行業。

行政長官:2023年博彩業佔本地生產總值36.2%

行政長官賀一誠週日表示,2023年博彩業佔本地生產總值(GDP)的36.2%,符合政府設定的經濟多元化目標。